RxDoctor Payments Data

Thuy Mong Strong

Optometrist · Columbia, MDNPI 1871634972

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,936 of the $4,803 with a category attached, or 81.9%. 20 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 34.3% of the total. Among optometrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,803in general payments, 2019–2025

Across 130 payments — averaging $36.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Sun Pharmaceutical Industries Inc.$697
  • Bausch & Lomb Americas Inc.$448
  • Tarsus Pharmaceuticals, Inc.$444
  • Alcon$410
  • Novartis$245
  • plus $914 from 14 others

What the payments were for

  • Consulting fees$85018%
  • Food & beverage$3,93682%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,803 in reported general payments places this provider in the 95th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$15,643
Medicare patients
45
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CequaCyclosporine12$10,237
MieboPerfluorohexyloctane/Pf12$8,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa$697$10,23712 claims
Bausch & Lomb Americas Inc.Miebo$448$8,92012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 optometrist providers in Maryland.

Other optometrist in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →